project . 2020 - 2022 . On going

CoroNAb

Nanobodies and antibodies against 2019-nCoV
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 101003653 Call for proposal: H2020-SC1-PHE-CORONAVIRUS-2020
  • Funded under: H2020 | RIA Overall Budget: 2,771,660 EURFunder Contribution: 2,771,660 EUR
  • Status: On going
  • Start Date
    01 Apr 2020
    End Date
    31 Mar 2022
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Overview: As of Feb 12th, 2020, the death toll of the 2019-nCoV (COVID-19) epidemic has surpassed 1000, rapidly eclipsing the total mortality of SARS. It has a current death rate estimate of around 2 deaths per 100 confirmed infections, is experiencing phenomenal growth in mainland China, and has the potential to spread globally over the coming months. While a vaccine may be useful for future epidemics of a similar virus, it is not clear that such a vaccine can be produced at a speed and scale sufficient to impact the current epidemic. Objective: Antibodies form the basis of a robust adaptive immune response to viral disease. Nearly all licensed vaccines mediate...
Description
Overview: As of Feb 12th, 2020, the death toll of the 2019-nCoV (COVID-19) epidemic has surpassed 1000, rapidly eclipsing the total mortality of SARS. It has a current death rate estimate of around 2 deaths per 100 confirmed infections, is experiencing phenomenal growth in mainland China, and has the potential to spread globally over the coming months. While a vaccine may be useful for future epidemics of a similar virus, it is not clear that such a vaccine can be produced at a speed and scale sufficient to impact the current epidemic. Objective: Antibodies form the basis of a robust adaptive immune response to viral disease. Nearly all licensed vaccines mediate...
Any information missing or wrong?Report an Issue